Literature DB >> 12519873

Characterization of human NOV in biological fluids: an enzyme immunoassay for the quantification of human NOV in sera from patients with diseases of the adrenal gland and of the nervous system.

H Thibout1, C Martinerie, C Créminon, F Godeau, P Boudou, Y Le Bouc, M Laurent.   

Abstract

Immunochromatography has shown that human NOV (NOVH), a member of the CCN (CTGF/CYR61/NOV) family, forms a physiological complex with fibulin-1 in blood. We developed an enzyme immunoassay specific for NOVH and showed for the first time that the concentration of NOVH differs in each of these biological fluids. The normal concentration of NOVH circulating in the blood is 350-400 ng/ml, but this concentration varies with age. By using sera from patients with adrenal gland diseases we found that in vivo ACTH or glucocorticoids are not responsible for the high concentration of NOVH in this endocrine gland. However, the NOVH concentration was significantly modified in malignant adrenocortical tumors, but not in benign adrenocortical tumors. The concentration of NOVH was significantly decreased in patients suffering from astrocytomas or multiple sclerosis, two diseases of the nervous system. Thus, NOVH is a potentially useful marker for the diagnosis of these diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519873     DOI: 10.1210/jc.2002-020304

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Canonical and non-canonical Notch ligands.

Authors:  Brendan D'Souza; Laurence Meloty-Kapella; Gerry Weinmaster
Journal:  Curr Top Dev Biol       Date:  2010       Impact factor: 4.897

Review 2.  The CCN proteins: important signaling mediators in stem cell differentiation and tumorigenesis.

Authors:  Guo-Wei Zuo; Christopher D Kohls; Bai-Cheng He; Liang Chen; Wenli Zhang; Qiong Shi; Bing-Qiang Zhang; Quan Kang; Jinyong Luo; Xiaoji Luo; Eric R Wagner; Stephanie H Kim; Farbod Restegar; Rex C Haydon; Zhong-Liang Deng; Hue H Luu; Tong-Chuan He; Qing Luo
Journal:  Histol Histopathol       Date:  2010-06       Impact factor: 2.303

Review 3.  The many facets of Notch ligands.

Authors:  B D'Souza; A Miyamoto; G Weinmaster
Journal:  Oncogene       Date:  2008-09-01       Impact factor: 9.867

4.  First structural glimpse of CCN3 and CCN5 multifunctional signaling regulators elucidated by small angle x-ray scattering.

Authors:  Kenneth P Holbourn; Marc Malfois; K Ravi Acharya
Journal:  J Biol Chem       Date:  2011-05-04       Impact factor: 5.157

5.  Effects of resveratrol and its analogue pterostilbene, on NOV/CCN3 adipokine in adipose tissue from rats fed a high-fat high-sucrose diet.

Authors:  J Trepiana; S Gómez-Zorita; Alfredo Fernández-Quintela; M González; M P Portillo
Journal:  J Physiol Biochem       Date:  2019-04-11       Impact factor: 4.158

6.  CCN3/NOV small interfering RNA enhances fibrogenic gene expression in primary hepatic stellate cells and cirrhotic fat storing cell line CFSC.

Authors:  Erawan Borkham-Kamphorst; Claudia R van Roeyen; Eddy Van de Leur; Jürgen Floege; Ralf Weiskirchen
Journal:  J Cell Commun Signal       Date:  2011-07-05       Impact factor: 5.782

7.  NOV/CCN3 attenuates inflammatory pain through regulation of matrix metalloproteinases-2 and -9.

Authors:  Lara Kular; Cyril Rivat; Brigitte Lelongt; Claire Calmel; Maryvonne Laurent; Michel Pohl; Patrick Kitabgi; Stéphane Melik-Parsadaniantz; Cécile Martinerie
Journal:  J Neuroinflammation       Date:  2012-02-21       Impact factor: 8.322

8.  Plasma NOV/CCN3 levels are closely associated with obesity in patients with metabolic disorders.

Authors:  Jihane Pakradouni; Wilfried Le Goff; Claire Calmel; Bénédicte Antoine; Elise Villard; Eric Frisdal; Marianne Abifadel; Joan Tordjman; Christine Poitou; Dominique Bonnefont-Rousselot; Randa Bittar; Eric Bruckert; Karine Clément; Bruno Fève; Cécile Martinerie; Maryse Guérin
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

9.  Nov/Ccn3, a novel transcriptional target of FoxO1, impairs pancreatic β-cell function.

Authors:  Renée Paradis; Noureddine Lazar; Peter Antinozzi; Bernard Perbal; Jean Buteau
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  Reduced NOV/CCN3 Expression Limits Inflammation and Interstitial Renal Fibrosis after Obstructive Nephropathy in Mice.

Authors:  Pierre-Olivier Marchal; Panagiotis Kavvadas; Ahmed Abed; Chantal Kazazian; Florence Authier; Haruhiko Koseki; Shuichi Hiraoka; Jean-Jacques Boffa; Cécile Martinerie; Christos E Chadjichristos
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.